

.....  
**Report of the WHO  
Informal Consultation  
on the use of chemotherapy  
for the control of morbidity  
due to soil-transmitted  
nematodes in humans**

.....  
**Geneva  
29 April to 1 May 1996**



**World Health Organization  
Geneva  
Schistosomiasis and Intestinal Parasites Unit  
Division of Control of Tropical Diseases  
[www.who.ch/ctd](http://www.who.ch/ctd)**

REPORT OF THE  
WHO INFORMAL CONSULTATION ON THE  
USE OF CHEMOTHERAPY FOR THE CONTROL OF MORBIDITY  
DUE TO SOIL-TRANSMITTED NEMATODES IN HUMANS

GENEVA  
29 April to 1 May 1996

Schistosomiasis and Intestinal Parasites Unit  
Division of Control of Tropical Diseases

This Consultation was financially supported by:

Direzione Generale Cooperazione allo Sviluppo  
Italian Ministry of Foreign Affairs

If tht is not iswld ID tho go....l public. ond oil righU  
I by thl World Hnlth Orgnization IWHOI. Tha  
tay not bl raviewll. abstractll. quotd , nprodud or  
1 pan or in whoil, without tha prior wnnan parmlilon  
a pan of this document may ba nold in a raniml  
Tifilm!Uid in any form or by any mnna - altctronic.  
or othar . Without tha prior wrinan pormllion of

xprasld "" dacumtnu by namld authors 111 solely tha  
1 at tho•authors.

Ci document n'nt pu dntin6 ■ lira dislribu6 au grand public 11 taus  
111 droiu y alliranu sont risi!Ws p• l'Orgamsation mondiala da la  
Santi IOMSI. 11 na paut Itrl commanti, risumi. citi. raproduit ou  
traduit. Pl"lliamant ou an IDIIIIti, sans una autorillion priaialbl  
icritu dl l'OMS. Aucuna partI na doit **tm dlllgH** dans un systiml da  
rachmha documantaia ou diffusil sous qualqua forma ou par qualqua  
moyan que Ci SoII . ilactroniqua. micaniqut, ou autra • 11ns una  
IUOIIIIIian priaialbla ictilI dl l'OMS.

La opinions nprim..s dans In daculllna PI' das aullurs citis  
nammimant n'an!IQml qualadiU autrurs.

## Table of Contents

	<b>Page no.</b>
List of Participants	5
1. Opening Ceremony	8
2. Purpose of the Consultation	10
3. Essential Epidemiology	11
4. Review of available anthelminthic drugs (Tables 4.1 and 4.2)	12
4.1 Albendazole	15
4.2 Ivermectin	16
4.3 Levamisole	17
4.4 Mebendazole	18
4.5 Pyrantel	19
4.6 Rationale for the Choice of Drugs (Tables 4.1 and 4.2)	20
4.6.1 Quality	20
4.6.2 Costs	21
5. Examples of the Control of Soil-transmitted Nematodes using Chemotherapy	21
5.1 Self-sustained programmes in Japan	21
5.1.1 Historical Account	22
5.1.2 Tripartite Co-operation	23
5.1.3 Japanese Organization for International Co-operation in Family Planning (JOICFP)	23
5.2 Control of soil-transmitted nematodes in areas of low prevalence: Seychelles experience	24
5.2.1 Planning, coordination and management	24
5.2.2 Control measures: Periodic chemotherapy and health education	25
5.2.3 Monitoring and sustainability	26

5.3 Control of soil-transmitted nematodes in areas of high prevalence: Zanzibar experience	26
5.3.1 Planning, coordination and management	26
5.3.2 Monitoring and evaluation	27
5.4 Use of anthelminthic chemotherapy in high risk groups in Sri Lanka	28
5.4.1 Children and provision of anthelminthic chemotherapy to children	28
5.4.2 Provision of anthelminthic chemotherapy to pregnant women	30
5.5 Monitoring large-scale integrated control programmes: the Mexican experience	31
5.5.1 Objectives of the intervention	31
5.5.2 Social and community mobilization .	32
5.5.3 Training of health personnel	32
5.5.4 Surveys and Evaluation	32
5.5.5 Results	32
5.5.6 Merits	34
5.6 Developments in the control of <i>Strongyloides stercoralis</i>	34
5.6.1 Previous experience	34
5.6.2 Zanzibar experience, 1994	35
5.6.3 Results and Conclusions	35
6. Approaches to the wider control of helminthiases: opportunities for integration	36
6.1 Chemotherapy for onchocerciasis	36
6.1.1 Onchocerciasis	36
6.1.2 Clinic-based/pассив drug delivery	36
6.1.3 Active drug delivery	37
6.1.4 Integration into the PHC.	37
6.1.5 Community self-treatment of onchocerciasis with Ivermectin.	37

6.2 Controlling lymphatic filariasis	38
6.2.1 Tools and strategies	38
6.2.2 Integration of intestinal nematode control and filaria(nematode control)	39
7. Some operational features of anthelmintic chemotherapy	40
7.1 Determination of the appropriate interval for chemotherapy	40
7.2 Delivery of anthelminthic drugs through schools: The Partnership for Child Development	41
8. Awareness of the potential threat of drug resistance by soil-transmitted nematodes and other helminth infections	42
8.1 Theoretical considerations	42
8.2 Experience of anthelminthic drug resistance in nematodes of veterinary importance	43
8.2.1 Recognition of drug resistance	43
8.3 Experience of anthelminthic drug resistance in schistosome populations.	44
8.3.1 Monitoring drug usage and surveillance for emerging drug resistance.	44
9. Recommendations	45
10. Topics for operational research	47
11. References..	51

## List of Participants

Dr M. Albonico, Fondazione Ivo de Cameri, via G. Ceradini 3, Milano, 20129, Italy

Professor D.A.P. Bundy, WHO Collaborating Centre for Epidemiology of Intestinal Parasitic Infections, University of Oxford, South Parks Road, Oxford OX1 3PS, United Kingdom

Dr G.C. Coles, Dept. of Clinical Veterinary Science, University of Bristol, Langford House, Langford, Bristol BS18 7DU, United Kingdom

Professor D.W.T. Crompton, WHO Collaborating Centre for Soil- transmitted Helminthiases, Institute of Biomedical and Life Sciences, University of Glasgow, Graham Kerr Building, Glasgow G12 8QQ, United Kingdom  
**(Rapporteur)**

Dr Andrew Hall, Partnership for Child Development, University of Oxford, South Parks Road, Oxford OX1 3PS, United Kingdom

Dr Shigeo Hayashi, c/o Hokenhaikan, 1-2 Sadohara-Cho. Ichigaya, Shinjuku-Ku, Tokyo 162, Japan **(Chairman)**

ProfM. Mahrooflsmail, Dean, Faculty of Medicine, University of Colombo, P.O. Box 271, Kynsey Road, Colombo 8, Sri Lanka

Dr Uledi M. Kisumu, Deputy Principal Secretary, Ministry of Health, P.O. Box 236, Zanzibar, Republic of Tanzania

Professor Akio Kobayashi, Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-ku, Tokyo 105, Japan

Dr Hanspeter Marti, Swiss Tropical Institute, Socinstr. 57, 4002 Basel, Switzerland

Dr E. Renganathan, Italian-Egyptian Cooperation, Medical Research Institute, University of Alexandria, 165, El Horreya Street, Alexandria, Egypt

Dr J. Tielsch, School of Hygiene and Public Health, Department of International Health, Johns Hopkins University, 615 North Wolfe Street, Room 5515, Baltimore, MD 212 05-2103, USA

Dr Jose Luis Valdespino Gomez, Secretario Academico, Instituto Nacional de Salud Publica, Av. Universidad 655, Col. Sta. Maria Ahuacatitlan, C.P. 62508, Cuernavaca, Morelos, Mexico

### **Observers**

Mr D. McIntosh, Medical Affairs Department, ZENECA Pharmaceuticals, United Kingdom

Dr A. Olsen, Parasitologist, Danish Bilharziasis Laboratory, Denmark

Dr P. Magnussen, Parasitologist, Danish Bilharziasis Laboratory, Denmark

Dr J. Horton, Head of Therapeutics (Tropical Medicine), International Medical Department, SmithKline Beecham, United Kingdom

Dr M. Booth, Department of Public Health and Epidemiology, Swiss Tropical Institute, Base!, Switzerland

## WHO Secretariat

Dr R.H. Henderson, ADG  
Dr P. Ngoumou, RA/AFRO  
Dr K. Behbehani, Director CID  
Dr D.L. Heymann, Director EMC  
Dr C.D. Ginger, OCP  
Ms T. Jorgensen, CID/SIP  
Dr A. Montresor, CID/SIP  
Dr L. Savioli, CID/SIP  
Dr E. Ottesen, CID/FIL  
Dr Yu Sen-hai, HPR  
Dr M. Couper, DMP  
Dr M. Mokbel, FNU/FAP  
Dr D. Evans, IDRITDF  
Dr J.H.F. Remme, TDRITDF  
Dr W.E. Gutteridge, IDRITDP  
Dr R. Guidotti, RHT/MSM

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30663](https://www.yunbaogao.cn/report/index/report?reportId=5_30663)

